INOZYME PHARMA ($INZY) is expected to release its quarterly earnings data on Monday, August 4th before market open, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.37 per share.
You can see Quiver Quantitative's $INZY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INOZYME PHARMA Insider Trading Activity
INOZYME PHARMA insiders have traded $INZY stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $INZY stock by insiders over the last 6 months:
- DOUGLAS A TRECO (CEO & Chairman) sold 8,819 shares for an estimated $7,848
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
INOZYME PHARMA Hedge Fund Activity
We have seen 38 institutional investors add shares of INOZYME PHARMA stock to their portfolio, and 53 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EVENTIDE ASSET MANAGEMENT, LLC removed 2,220,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,020,200
- SATURN V CAPITAL MANAGEMENT LP removed 875,328 shares (-63.7%) from their portfolio in Q1 2025, for an estimated $796,548
- FMR LLC removed 645,806 shares (-35.4%) from their portfolio in Q1 2025, for an estimated $587,683
- MILLENNIUM MANAGEMENT LLC removed 637,552 shares (-33.9%) from their portfolio in Q1 2025, for an estimated $580,172
- CITADEL ADVISORS LLC removed 436,894 shares (-70.8%) from their portfolio in Q1 2025, for an estimated $397,573
- ROCK SPRINGS CAPITAL MANAGEMENT LP removed 416,684 shares (-10.8%) from their portfolio in Q1 2025, for an estimated $379,182
- ABERDEEN GROUP PLC removed 326,758 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,307,032
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
INOZYME PHARMA Analyst Ratings
Wall Street analysts have issued reports on $INZY in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/10/2025
- Raymond James issued a "Outperform" rating on 03/12/2025
- Piper Sandler issued a "Overweight" rating on 03/11/2025
To track analyst ratings and price targets for INOZYME PHARMA, check out Quiver Quantitative's $INZY forecast page.
INOZYME PHARMA Price Targets
Multiple analysts have issued price targets for $INZY recently. We have seen 6 analysts offer price targets for $INZY in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Tiago Fauth from Wells Fargo set a target price of $4.0 on 05/16/2025
- Ryan Deschner from Jefferies set a target price of $4.0 on 05/16/2025
- Joseph Stringer from Needham set a target price of $12.0 on 05/16/2025
- Edward White from HC Wainwright & Co. set a target price of $16.0 on 04/10/2025
- Ryan Deschner from Raymond James set a target price of $12.0 on 03/12/2025
- Allison Bratzel from Piper Sandler set a target price of $23.0 on 03/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
